Oral intake of Kluyveromyces marxianus B0399 plus Lactobacillus rhamnosus CECT 30579 to mitigate symptoms in COVID-19 patients: A randomized open label clinical trial.

Med Microecol · 2022 · PMC9398813 · PMID 36035620

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

almost significantno p-value reported

Moreover, despite the low number of patients in our study, the magnitude of the difference in the number of patients showing a completely resolution of symptoms comparing control and probiotic group reaches almost significant statistical difference (13% vs 41.7%; p value = 0.06).

also in 1,858 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.